Late stent thrombosis with drug-eluting stents

the price to pay to prevent restenosis?

Dharam J. Kumbhani, Anthony A. Bavry, Deepak L. Bhatt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Drug-eluting stents have revolutionized the management of patients with coronary artery disease by decreasing the incidence of restenosis and the need for repeat revascularization. Recent data indicate that they may, however, be associated with a small but significant increase in the risk of late stent thrombosis compared with bare-metal stents. In this review, we discuss the incidence, pathogenesis, and predictors of stent thrombosis, the most important being premature cessation of dual antiplatelet therapy. Drug-eluting stent implantation needs to be carefully considered in every patient, and the risk of stent thrombosis and bleeding needs to be weighed against the risk of restenosis. Current guidelines recommend that dual antiplatelet therapy should be continued for at least 1 year following drug-eluting stent implantation, although the optimal duration of therapy is yet unknown.

Original languageEnglish (US)
JournalIndian Heart Journal
Volume59
Issue number2 Suppl B
StatePublished - Mar 2007

Fingerprint

Drug-Eluting Stents
Stents
Thrombosis
Incidence
Coronary Artery Disease
Therapeutics
Metals
Guidelines
Hemorrhage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Late stent thrombosis with drug-eluting stents : the price to pay to prevent restenosis? / Kumbhani, Dharam J.; Bavry, Anthony A.; Bhatt, Deepak L.

In: Indian Heart Journal, Vol. 59, No. 2 Suppl B, 03.2007.

Research output: Contribution to journalArticle

@article{d0db4b3861654643bf96e9c08f40f364,
title = "Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?",
abstract = "Drug-eluting stents have revolutionized the management of patients with coronary artery disease by decreasing the incidence of restenosis and the need for repeat revascularization. Recent data indicate that they may, however, be associated with a small but significant increase in the risk of late stent thrombosis compared with bare-metal stents. In this review, we discuss the incidence, pathogenesis, and predictors of stent thrombosis, the most important being premature cessation of dual antiplatelet therapy. Drug-eluting stent implantation needs to be carefully considered in every patient, and the risk of stent thrombosis and bleeding needs to be weighed against the risk of restenosis. Current guidelines recommend that dual antiplatelet therapy should be continued for at least 1 year following drug-eluting stent implantation, although the optimal duration of therapy is yet unknown.",
author = "Kumbhani, {Dharam J.} and Bavry, {Anthony A.} and Bhatt, {Deepak L.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "59",
journal = "Indian Heart Journal",
issn = "0019-4832",
publisher = "Cardiology Society of India",
number = "2 Suppl B",

}

TY - JOUR

T1 - Late stent thrombosis with drug-eluting stents

T2 - the price to pay to prevent restenosis?

AU - Kumbhani, Dharam J.

AU - Bavry, Anthony A.

AU - Bhatt, Deepak L.

PY - 2007/3

Y1 - 2007/3

N2 - Drug-eluting stents have revolutionized the management of patients with coronary artery disease by decreasing the incidence of restenosis and the need for repeat revascularization. Recent data indicate that they may, however, be associated with a small but significant increase in the risk of late stent thrombosis compared with bare-metal stents. In this review, we discuss the incidence, pathogenesis, and predictors of stent thrombosis, the most important being premature cessation of dual antiplatelet therapy. Drug-eluting stent implantation needs to be carefully considered in every patient, and the risk of stent thrombosis and bleeding needs to be weighed against the risk of restenosis. Current guidelines recommend that dual antiplatelet therapy should be continued for at least 1 year following drug-eluting stent implantation, although the optimal duration of therapy is yet unknown.

AB - Drug-eluting stents have revolutionized the management of patients with coronary artery disease by decreasing the incidence of restenosis and the need for repeat revascularization. Recent data indicate that they may, however, be associated with a small but significant increase in the risk of late stent thrombosis compared with bare-metal stents. In this review, we discuss the incidence, pathogenesis, and predictors of stent thrombosis, the most important being premature cessation of dual antiplatelet therapy. Drug-eluting stent implantation needs to be carefully considered in every patient, and the risk of stent thrombosis and bleeding needs to be weighed against the risk of restenosis. Current guidelines recommend that dual antiplatelet therapy should be continued for at least 1 year following drug-eluting stent implantation, although the optimal duration of therapy is yet unknown.

UR - http://www.scopus.com/inward/record.url?scp=63249112287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249112287&partnerID=8YFLogxK

M3 - Article

VL - 59

JO - Indian Heart Journal

JF - Indian Heart Journal

SN - 0019-4832

IS - 2 Suppl B

ER -